Perkins Coie Trust Co trimmed its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 24.3% during the first quarter, HoldingsChannel.com reports. The firm owned 4,827 shares of the exchange traded fund’s stock after selling 1,550 shares during the period. Perkins Coie Trust Co’s holdings in SPDR S&P Biotech ETF were worth $391,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in XBI. Demars Financial Group LLC acquired a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter valued at about $280,309,000. BlueCrest Capital Management Ltd acquired a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter valued at about $138,051,000. RA Capital Management L.P. acquired a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth approximately $110,615,000. Proficio Capital Partners LLC lifted its stake in shares of SPDR S&P Biotech ETF by 16,156.1% in the fourth quarter. Proficio Capital Partners LLC now owns 917,329 shares of the exchange traded fund’s stock worth $82,615,000 after acquiring an additional 911,686 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $55,529,000.
SPDR S&P Biotech ETF Price Performance
Shares of XBI stock opened at $84.26 on Friday. The business’s 50 day simple moving average is $78.33 and its 200 day simple moving average is $86.71. SPDR S&P Biotech ETF has a one year low of $66.66 and a one year high of $105.47. The stock has a market capitalization of $4.99 billion, a PE ratio of 11.47 and a beta of 0.85.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Top Stocks Investing in 5G Technology
- MarketBeat Week in Review – 06/02 – 06/06
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
- What Does a Stock Split Mean?
- 3 Stocks Getting Rare Double Upgrades From Analysts
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.